Patients who developed HCC during the study period were more likely to be older, male, have lower HBV DNA levels, alanine aminotransferase (ALT) levels, and platelet counts; but a higher fibrosis 4 (FIB-4) index and modified platelet age gender–HBV (mPAGE-B) score; and have used entecavir rather than TDF, compared with those who did not develop HCC (Supplemental Table 1; supplemental material available online with this article; https://doi.org/10.1172/JCI154833DS1). The gene discussed is GPT; the disease is hepatocellular carcinoma.